博雅生物(300294) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥466,151,253.70, an increase of 33.43% year-on-year, and a total of ¥1,473,924,123.26 for the first nine months, up 18.38% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2025 was ¥117,620,874.70, a year-on-year increase of 21.59%, while for the first nine months, it decreased by 16.90% to ¥342,961,782.60 due to inventory write-offs and asset depreciation from the acquisition of Green Cross[3] - The net profit excluding non-recurring gains and losses for Q3 2025 was ¥44,353,498.02, down 42.59% year-on-year, and for the first nine months, it was ¥209,904,556.55, a decrease of 37.55%[3] - The net cash flow from operating activities for the first nine months was ¥26,110,641.88, a significant decline of 90.05% compared to the previous year, attributed to the increased consolidation scope and reduced cash collections[3] - The total operating revenue for the current period is ¥1,473,924,123.26, representing an increase of 18.4% compared to ¥1,245,107,779.60 in the previous period[24] - The net profit for the current period is ¥343,042,957.61, a decrease of 16.8% from ¥412,432,277.86 in the previous period[26] - The basic and diluted earnings per share for the current period are both ¥0.68, down from ¥0.82 in the previous period[26] - The total comprehensive income for the current period is ¥340,003,097.84, down from ¥412,432,277.86 in the previous period[26] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥8,727,110,907.17, reflecting a 3.88% increase from the end of the previous year[2] - The company's total liabilities as of September 30, 2025, were RMB 1.055 billion, compared to RMB 913.38 million at the beginning of the period[21] - Shareholders' equity attributable to the parent company increased by 2.45% to ¥7,670,755,764.46 compared to the end of the previous year[2] - The company's equity attributable to shareholders increased to RMB 7.671 billion from RMB 7.487 billion at the beginning of the period[23] Cash Flow and Investments - Cash and cash equivalents decreased by 41.40% to ¥761,753,926.76, primarily due to investments in financial products and dividend payments[8] - Cash and cash equivalents at the end of the period decreased to ¥761,753,926.76 from ¥1,988,439,866.94 in the previous period[30] - The company reported a net cash outflow from investing activities of ¥363,760,941.02, compared to a smaller outflow of ¥53,563,157.00 in the previous period[30] Operational Costs - Operating costs rose by 62.63% to ¥675,003,264.47, mainly due to the consolidation of Green Cross[10] - The total operating costs increased to ¥1,228,094,382.40, up 44% from ¥853,438,255.57 in the previous period[24] - Management expenses increased by 72.98% to ¥220,993,490.91, attributed to the consolidation of Green Cross[10] - Cash paid for purchasing goods and services rose by 66.66% to ¥556,386,378.20, primarily due to the consolidation of Green Cross[10] - Cash paid for employee compensation increased by 33.06% to ¥290,389,236.50, attributed to the consolidation of Green Cross[10] - The company incurred sales expenses of ¥293,128,543.42, an increase from ¥273,785,234.14 in the previous period[24] - Research and development expenses decreased to ¥36,855,903.92 from ¥47,378,915.31 in the previous period[24] Accounts and Other Assets - Accounts receivable increased by 44.61% to ¥648,544,110.03, mainly due to slower collections influenced by medical insurance cost control and market conditions[8] - The company reported a total of RMB 1.119 billion in inventory as of September 30, 2025, up from RMB 995.43 million at the beginning of the period[19] - The company reported a significant increase in other current assets by 3170.55% to ¥36,999,645.23, mainly due to prepaid income tax and VAT[8] - The construction in progress rose by 149.43% to ¥800,666,347.63, driven by increased investment in the smart factory project[8] - Contract liabilities increased by 40.64% to ¥5,733,246.86, primarily due to an increase in advance payments[10] Investments and Dividends - Investment income surged by 218.28% to ¥24,863,589.47, primarily from the disposal of Boya Xinheng equity[10] - Minority interests increased by 176.71% to ¥1,692,999.32, mainly due to new investments from minority shareholders in the newly established Dalateqi Pulp Station[10] - Cash received from the disposal of subsidiaries and other operating units increased by 44.53% to ¥158,160,797.81, mainly from the disposal of Boya Xinheng equity[10] - Cash paid for fixed assets and intangible assets surged by 246.11% to ¥412,844,043.06, primarily due to payments for the smart factory project[10] - The company plans to publicly transfer 80% of its stake in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. through the Shanghai United Assets and Equity Exchange[14] - The transfer price for the 80% stake in Boya Xinhao was adjusted to RMB 158.1655 million, reflecting a 5.76% reduction from the original valuation[15] - After the completion of the stake transfer, the company holds a 10.6869% stake in Boya Xinhao, which is no longer included in the consolidated financial statements[16] - The company announced a cash dividend of RMB 1.50 per 10 shares, totaling RMB 75.6373 million, which represents 33.57% of the net profit attributable to shareholders for the first half of 2025[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,204[13]